Please check your internet connection and try again.
# Linagliptin
## Overview
Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin hormone concentrations, stimulating glucose-dependent insulin release and decreasing glucagon levels. Unlike other DPP-4 inhibitors, it is primarily excreted via the biliary tract and does not require renal dose adjustments.
## Primary Indications
Type 2 diabetes mellitus (T2DM) as an adjunct to diet and exercise to improve glycemic control.
## Adult Dosing
5 mg orally once daily. May be taken with or without food.
## Pediatric Dosing
Safety and efficacy have not been established in patients younger than 18 years. Use is generally not recommended in pediatric populations.
## Dose Adjustments
No dose adjustments are necessary for patients with renal impairment (including end-stage renal disease) or hepatic impairment.
## Contraindications
* Hypersensitivity to linagliptin.
* History of serious hypersensitivity reactions (e.g., anaphylaxis, angioedema, exfoliative skin conditions) to DPP-4 inhibitors.
* Not indicated for the treatment of Type 1 diabetes or diabetic ketoacidosis.
## Adverse Effects
* Common: Nasopharyngitis, increased uric acid, hyperlipidemia.
* Serious: Acute pancreatitis (discontinue if suspected), severe hypersensitivity/dermatologic reactions, bullous pemphigoid, severe joint pain (arthralgia).
## Key Drug Interactions
* **Strong CYP3A4/P-gp Inducers (e.g., rifampin):** May decrease linagliptin efficacy; monitor glycemic control if co-administration cannot be avoided.
* **Insulin/Sulfonylureas:** Risk of hypoglycemia is increased; consider dose reduction of the insulin secretagogue.
## Monitoring
* HbA1c (typically every 3–6 months).
* Blood glucose monitoring (especially when used with insulin or sulfonylureas).
* Monitor for signs/symptoms of pancreatitis (persistent, severe abdominal pain).
* Assess for unexplained severe joint pain or skin blistering.
## Clinical Pearls
* No renal dose adjustment required—the only DPP-4 inhibitor with this profile.
* Weight neutral; low intrinsic risk of hypoglycemia when used as monotherapy.
* If a dose is missed, take it as soon as possible on the same day; do not double the dose.
* Linagliptin is a weak inhibitor of P-glycoprotein, but generally does not cause clinically significant drug-drug interactions with narrow therapeutic index P-gp substrates (e.g., digoxin).
***
*Disclaimer: This information is for educational purposes and does not replace professional clinical judgment. Always verify current prescribing information, institutional guidelines, and manufacturer package inserts before prescribing or administering medication.*
